» Articles » PMID: 16002023

Mortality in Heroin-assisted Treatment in Switzerland 1994-2000

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2005 Jul 9
PMID 16002023
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A major goal of heroin-assisted treatment in Switzerland has been to reduce the drug-related mortality of heroin users. Therefore, a continuous monitoring of deaths under treatment is essential.

Aims: To assess mortality of participants in heroin-assisted treatment in Switzerland over a 7-year period from 1994 to 2000, and to compare this mortality to the general population and to other populations of opioid users, as reported in the literature.

Method: Estimation of person years under heroin-assisted treatment from the complete case registry of heroin-assisted treatment in Switzerland. Estimation of standardized mortality ratios comparing the population in treatment to the Swiss population (standardized to the year 2000).

Results: Over the 7-year period, the crude death rate of patients in heroin-assisted treatment, and including one month after discharge from treatment, was 1% per year. The standardized mortality ratio for the entire observation period was 9.7 (95% C.I. 7.3-12.8), with females having higher standardized mortality ratios (SMR 17.2) than males (SMR 8.4). There was no clear time trend.

Conclusion: Mortality in heroin-assisted treatment was low compared to the mortality rate of Swiss opioid users 1990s (estimated to be between 2.5 and 3%). It was also low compared to mortality rates of opioid users in other maintenance treatments in other countries as reported in the literature. The SMR was also lower than that reported in the only meta-analysis in the literature: 13.2 (95% C.I. 12.3-14.1). The low mortality rate is all the more noteworthy as heroin-assisted treatment in Switzerland included only refractory opioid addicts with existing severe somatic and/or mental problems.

Declaration Of Interest: No conflicts of interest declared.

Citing Articles

Challenges for the implementation of injectable opioid agonist treatment: a scoping review.

Schwarz T, Akartuna D, Busch M, Krausz R, Uhl A Harm Reduct J. 2024; 21(1):217.

PMID: 39633369 PMC: 11619471. DOI: 10.1186/s12954-024-01102-x.


Perceptions of prospective pharmaceutical stimulant substitution treatments among people who use illicit stimulants in Vancouver, Canada.

Fleming T, Ivsins A, Barker A, Mansoor M, Mayer S, Vakharia S Int J Drug Policy. 2024; 125:104336.

PMID: 38281384 PMC: 11045237. DOI: 10.1016/j.drugpo.2024.104336.


The Accessibility of Opioid Agonist Treatment and Its Forced Discontinuation in Swiss Prisons-Attitudes, Perceptions and Experiences of Defense Lawyers in Dealing With Detained Persons Using Opioids.

Buadze A, Baggio S, Schleifer R, Aeberhard E, Wolff H, Schneeberger A Front Psychiatry. 2020; 11:395.

PMID: 32477183 PMC: 7240251. DOI: 10.3389/fpsyt.2020.00395.


Circumstances of overdose among street-involved, opioid-injecting women: Drug, set, and setting.

Ataiants J, Roth A, Mazzella S, Lankenau S Int J Drug Policy. 2020; 78:102691.

PMID: 32086154 PMC: 7302961. DOI: 10.1016/j.drugpo.2020.102691.


Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis.

Aldridge R, Story A, Hwang S, Nordentoft M, Luchenski S, Hartwell G Lancet. 2017; 391(10117):241-250.

PMID: 29137869 PMC: 5803132. DOI: 10.1016/S0140-6736(17)31869-X.